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Objectives: Foot ulceration is a major cause of disability in diabetic patients. 
Disability of patients with diabetic foot ulceration (DFS – Diabetic Foot Syndrome) 
concerns not only patients themselves, but also the informal caregivers, mainly 
their close relatives. The aim of this study was to estimate lost productivity in 
a population of family caregivers of patients with diabetic foot ulceration in 
Poland. MethOds: A survey among 189 patients with DFS (treated in ambulatory 
care) and their families was conducted. To assess the impact of diabetic ulceration 
on productivity of caregivers to DFS patients the modified questionnaire WPAI-CG 
was used. The PEDIS scale was used to classify severity of ulceration. Results: A 
total of 116 out of 189 questionnaires were collected, and data on 93 responders 
(25 males) were included in the analysis (23 questionnaires were returned empty 
or concluded that informal care is not provided to DFS patients). Fifty-two (13 
males) out of 93 caregivers were employed at the time of the survey. Mean age 
of the population of caregivers was 45.9±11.2 years. Most were close relatives of 
DFS patients (58% spouses, 27% children). Almost half caregivers were employed 
in private sector (46%). Most had higher (50%) or secondary (48%) education. The 
average weekly work time declared was 40.4±13.1 hours. Approximately 70% of 
caregivers were urban population. The average percentage of work time missed 
and the percentage of working impairment while working due to informal care 
of DFS patients were estimated at 11.9% and 25.0%, respectively. The percentage 
of overall work impairment due to informal care of DFS patients was 32.2%. This 
amounts to weekly average time of the absence of 13.0 hours. cOnclusiOns: 
The lost productivity due to informal care on DFS patients is substantial and may 
have important implications for the economy.
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Objectives: GLP-1 agonists in combination with basal insulin (BI) have demon-
strated additional improvement of glycemic control in uncontrolled T2DM patients 
in clinical trials. It is therefore important to assess the real-world utilisation of 
GLP-1 agonists in combination with BI in T2DM patients. MethOds: Retrospective 
cohort analysis (2010 to 2012) to assess GLP-1 agonist utilisation in T2DM patients 
based on the Norwegian Institute of Public Health Prescription Database (NorPD). 
Both ICPC= T90 and ICD-10= E11 were applied to identify T2DM patients. Patients 
who had ≥ 2 GLP-1 dispensed within 6-month in Year-2011, with 1-year pre-Base-
line/post- Follow-up GLP-1 initiation were included in the analysis. Baseline anti-
diabetic drug use and combination use of GLP-1 and BI at Follow-up were also 
assessed. Results: Of the 1,500 GLP-1 initiators identified (mean age= 57; 52% 
male) at Baseline, 77% were on OADs, 19% on BI, 2% on prandial insulin (no BI) 
and 2% on other/no anti-diabetic drug. During 1-year Follow-up of GLP-1 adding 
on OADs patient population, 56% used GLP-1 continuously including 50% who 
used GLP-1 alone and 6% added BI. In total, 15% had either combined with or 
switched to BI, 4 months after the first GLP-1 was dispensed. Of those GLP-adding 
on BI patient population, 53% continuously used GLP-1 including 26% had both 
GLP-1 and BI dispensed throughout the Follow-up. About 52% had either BI inter-
rupted or discontinued approximately 2 months after the first GLP-1 was dis-
pensed. In total, 27% had insulin bolus dispensed; of which 58% either interrupted 
or discontinued GLP-1. cOnclusiOns: About 1/3 of GLP-1 initiators were in com-
bination with BI. In BI treated T2DM patients > 25% remained on both GLP-1 and 
BI, while another > 25% required treatment augmentation or switched to bolus. 
The data suggests an unmet treatment need, particularly in T2DM patients treated 
with BI.
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Objectives: To provide a comprehensive and coherent reference document of 
published cost data for diabetic complications in France, Germany, Italy and Spain 
for use in economic diabetes modeling. MethOds: A search for published cost of 
diabetes complications data from a health care payer perspective was performed 
on government websites, in peer-reviewed journals and local cost experts. All costs 
were inflated to 2013 Euros (€ ). Results: First year costs of myocardial infarction 
varied between € 3,041 in France and € 9,690 in Germany. Heart failure costs were 
similar across countries: € 3,104 in France; € 2,791 in Germany; € 4,000 in Italy and 
€ 3,316 in Spain. Costs of non-fatal stroke were higher in Germany (€ 16,441) than in 
other countries (Spain € 8,016; Italy € 6,073; France € 5,447). Everywhere, the cost of 
haemodialysis was higher than peritoneal dialysis € 35,972 versus € 21,255 in Spain, 
€ 21,552 versus € 18,485 in Italy, € 34,290 versus € 34,069 in Germany € 71,683 versus 
€ 48,752 in France. Renal transplant cost was estimated to € 84,114 in France, € 34,858 
in Germany, € 38,528 in Italy and € 26,618 in Spain. The cost of a major hypoglycemia 
requiring medical care was € 4,275 in Spain, € 2,561 in Germany, € 1,391 in Italy and 
€ 1,165 in France. Neuropathy complication costs varied widely: € 3,808 (France); 
€ 16,762 (Germany); € 4,290 (Italy); and € 5,330 (Spain) for foot ulcers and € 6,056 (Italy); 
€ 7,754 (Germany); € 9,578 (France); and € 12,118 (Spain) for lower-extremity ampu-
tation. cOnclusiOns: This study provides a coherent set of costs for diabetes 
complications in four European countries. Due to the differences in health care 
Objectives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated efficacious blood glucose control, 
with less hypoglycaemic events, and with an option for flexibility in dose time, 
compared with insulin glargine (IGlar). The objective was to assess the cost-
effectiveness of IDeg in Belgium, compared with IGlar. The analysis focused on 
patients in three treatment regimens: T1DM, T2DM treated with basal insulin in 
combination with oral anti-diabetics (BOT) and T2DM treated with basal-bolus 
(BB). MethOds: A one-year cost-utility model driven by differences in hypogly-
caemia was used. Published dis-utilities for hypoglycaemic events were multiplied 
by the rate of hypoglycaemia to calculate quality-adjusted life years (QALYs). Costs 
and utilities were also calculated for potential use of less blood glucose test strips. 
A utility gain was attributed to the additional benefit of dosing flexibility. Unit 
costs pertained to public tariffs and reflected the payer perspective in Belgium. 
Baseline incidence rates of hypoglycaemic events and related resource utilization 
pertained to a Belgian patient-reported outcomes study. Hospitalization costs 
following severe hypoglycaemia were estimated using the IMS Hospital Disease 
Database. Results: IDeg was associated with an incremental cost-effectiveness 
ratio of 14,677€ /QALY in T1DM, 4,976€ /QALY in T2DM BOT, and 12,930€ /QALY in 
T2DM BB. Univariate and probabilistic sensitivity analyses confirmed robust 
results. Results were most sensitive to variations in number of IGlar doses per 
day, and number of glucose-monitoring tests. At a willingness to pay threshold of 
30,000€ /QALY, IDeg would be cost-effective in 54%, 100% and 93% of the cases in the 
T1DM, T2DM BOT or T2DM BB treatment regimens respectively. cOnclusiOns: 
These analyses demonstrate that IDeg is cost-effective in Belgium, when used 
in patients with T1DM and T2DM currently treated with long-acting insulin ana-
logues.
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Objectives: The analysis goal is to determine the cost-effectiveness of liraglutide 
as add-on to metformin in for patients with type 2 diabetes in condition of the 
Russian health care system. Total medical expenses and effectiveness in terms of 
QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combina-
tion with metformin, and metformin monotherapy. MethOds: Data were sourced 
from a clinical trial comparing liraglutide vs. glimepiride (in combination with 
metformin), and a clinical trial comparing liraglutide vs. rosiglitazone (as add-on to 
metformin). From them data on clinical effectiveness in form of impact on HbA1(c), 
body mass index and blood pressure are extracted. Utility values are mostly taken 
from the UK Prospective Diabetes Studies supplemented with other published 
sources. The analysis is conducted from the perspective of the Russian health care 
system. Respectively the cost of the following resources is accounted: comparing 
of alternatives, concomitant pharmacotherapy, cost of medical manipulation, cost 
of ambulatory visits. Both future costs and clinical benefits are discounted at 3 
percent. Sensitivity analysis is performed. Results of this analysis are shown in the 
incremental cost-utility rate (ICUR). Results: The data of the analysis illustrates 
that liraglutide therapy for type 2 diabetes patients provides a significant health 
improvement from the perspective of quality adjusted life-years. Simultaneously 
liraglutide demonstrates better cost-effectiveness than the compared alternatives. 
The ICUR index of 1.2 mg liraglutide in combination with metformin equal to 1 
348368 rub, 1 161874 rub and 537331 rub for QALY in comparison with metformin 
monotherapy, glimepiride and rosiglitazone, both in combination with metformin, 
respectively. cOnclusiOns: Liraglutide has turned to be cost-effective therapeu-
tic alternative for treatment of type 2 diabetes in adult patients in conditions of 
Russian health care system over a 10-year time horizon.
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Objectives: To evaluate the long-term cost effectiveness of sitagliptin com-
pared to glimepiride and acarbose in the treatment of type 2 diabetes mellitus in 
China. MethOds: Sitagliptin, as add-on therapy to metformin, was compared to 
glimepiride and acarbose, and as monotherapy was also compared to acarbose. 
The validated UKPDS Outcomes Model was used to estimate the direct medical 
costs and outcomes (life years and QALYs gained). The demographic characteris-
tics and clinical data were taken from published literature. The quality of life data 
was obtained from published literature and re-confirmed through a questionnaire 
survey from a clinical expert panel of 20 diabetes specialists. The cost of drugs 
was calculated based on government guidance price or actual market price. The 
annual cost of complications was estimated based on expert opinions. Patients’ 
outcomes were modeled for 40 years and incremental cost-effectiveness ratios 
were calculated. Both future costs and clinical benefits were discounted at 3 
percent. A probabilistic sensitivity analysis was performed to understand the key 
drivers and general sensitivity of the model. Results: The results showed that, 
compared to the treatment of glimepiride and acarbose plus metformin therapy, 
the add-on of sitagliptin provided a gain of 0.02 and 0.95 QALYs per patient, and 
the incremental cost-effectiveness ratios were USD 9,470 and USD 399, respec-
tively. The results also showed that compared to acarbose monotherapy (100mg 
t.i.d and 200mg t.i.d), the sitagliptin monotherapy (100mg/d and 200mg/d) was 
dominant, with higher QALYs (0.58 and 0.92) and years of life (0.72 and 1.23) 
gained and lower cost (USD 90 and USD 185). cOnclusiOns: According to the 
China’s GDP per capita in 2011 (USD 5,674), the results demonstrate that sitag-
liptin is more cost-effective than glimepiride and acarbose in the treatment of 
diabetes mellitus in China.
